Search

Your search keyword '"Bassett, Roland L."' showing total 453 results
Start Over Author "Bassett, Roland L." Publication Year Range Last 10 years
453 results on '"Bassett, Roland L."'

2. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant

Author

Pasvolsky, Oren, Bassett, Roland L., Ghanem, Sassine, Cuglievan, Branko, Tewari, Priti, Hosing, Chitra, Srour, Samer, Ramdial, Jeremy, Mahadeo, Kris M., Khazal, Sajad, Petropoulos, Demetrios, Popat, Uday, Qazilbash, Muzaffar, Kebriaei, Partow, Champlin, Richard, Shpall, Elizabeth J., and Nieto, Yago

Published
2023
Full Text
View/download PDF

3. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes

Author

Basho, Reva K., Zhao, Li, White, Jason B., Huo, Lei, Bassett, Roland L., Mittendorf, Elizabeth A., Thompson, Alastair, Litton, Jennifer K., Ueno, Naoto, Arun, Banu, Lim, Bora, Valero, Vicente, Tripathy, Debu, Zhang, Jianhua, Adrada, Beatriz E., Santiago, Lumarie, Ravenberg, Elizabeth, Seth, Sahil, Yam, Clinton, Moulder, Stacy L., and Damodaran, Senthil

Published
2024
Full Text
View/download PDF

5. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies

Author

Jelloul, Fatima Zahra, Quesada, Andres E., Yang, Richard K., Li, Shaoying, Wang, Wei, Xu, Jie, Tang, Guilin, Yin, C. Cameron, Fang, Hong, El Hussein, Siba, Khoury, Joseph, Bassett, Roland L., Garcia-Manero, Guillermo, Manasanch, Elizabet E., Orlowski, Robert Z., Qazilbash, Muzaffar H., Patel, Keyur P., Medeiros, L. Jeffrey, and Lin, Pei

Published
2023
Full Text
View/download PDF

8. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial

Author

Guadagnolo, B Ashleigh, Bassett, Roland L, Mitra, Devarati, Farooqi, Ahsan, Hempel, Caroline, Dorber, Courtney, Willis, Tiara, Wang, Wei-Lien, Ratan, Ravin, Somaiah, Neeta, Benjamin, Robert S, Torres, Keila E, Hunt, Kelly K, Scally, Christopher P, Keung, Emily Z, Satcher, Robert L, Bird, Justin E, Lin, Patrick P, Moon, Bryan S, Lewis, Valerae O, Roland, Christina L, and Bishop, Andrew J

Published
2022
Full Text
View/download PDF

12. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer

Author

Candelaria, Rosalind P., Spak, David A., Rauch, Gaiane M., Huo, Lei, Bassett, Roland L., Santiago, Lumarie, Scoggins, Marion E., Guirguis, Mary S., Patel, Miral M., Whitman, Gary J., Moulder, Stacy L., Thompson, Alastair M., Ravenberg, Elizabeth E., White, Jason B., Abuhadra, Nour K., Valero, Vicente, Litton, Jennifer, Adrada, Beatriz E., and Yang, Wei T.

Published
2022
Full Text
View/download PDF

13. Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis

Author

Laganà, Marta, primary, Balderrama-Brondani, Vania, additional, Herrera, Kelsey Ruth, additional, Chahla, Brenda, additional, Yaylaci, Feyza, additional, Bassett, Roland L, additional, Jimenez, Camilo, additional, Varghese, Jeena, additional, Waguespack, Steven G, additional, Campbell, Matthew T, additional, Shah, Amishi Y, additional, Rojas Hernandez, Cristhiam M, additional, and Habra, Mouhammed Amir, additional

Published
2024
Full Text
View/download PDF

14. Magnetic-Resonance-Imaging-Guided Cryoablation for Solitary-Biopsy-Proven Renal Cell Carcinoma: A Tertiary Cancer Center Experience

Author

Abdelsalam, Mohamed E., primary, Mecci, Nabeel, additional, Awad, Ahmed, additional, Bassett, Roland L., additional, Odisio, Bruno C., additional, Habibollahi, Peiman, additional, Lu, Thomas, additional, Irwin, David, additional, Karam, Jose A., additional, Matin, Surena F., additional, and Ahrar, Kamran, additional

Published
2024
Full Text
View/download PDF

16. Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-Term Outcomes in 144 Patients Over 6 Decades.

Author

Hensley, Sarah G, Hu, Mimi I, Bassett, Roland L, Ying, Anita K, Zafereo, Mark E, Perrier, Nancy D, Busaidy, Naifa L, Hyde, Samuel M, Grubbs, Elizabeth G, and Waguespack, Steven G

Subjects
MEDULLARY thyroid carcinoma, SYMPTOMS, OLDER patients, OVERALL survival, FAMILY history (Medicine), CHILD patients
Abstract

Context Sporadic medullary thyroid carcinoma (sMTC) rarely occurs in childhood and no studies have specifically focused on this entity. Objective To describe the clinical presentations and long-term outcomes of a large cohort of children and young adults with sMTC compared with hereditary MTC (hMTC). Methods Retrospective study of 144 patients diagnosed with MTC between 1961 and 2019 at an age ≤ 21 years and evaluated at a tertiary referral center. Results In contrast to hMTC (n = 124/144, 86%), patients with sMTC (n = 20/144, 14%) are older (P <.0001), have larger tumors (P <.0001), a higher initial stage grouping (P =.001) and have more structural disease (P =.0045) and distant metastases (DM) (P =.00084) at last follow-up, but are not more likely to die from MTC (P =.42). Among 77 patients diagnosed clinically, not by family history (20/20 sMTC and 57/124 hMTC), there was no difference in the initial stage (P =.27), presence of DM at diagnosis (P = 1.0), disease status at last follow-up (P =.13), overall survival (P =.57), or disease-specific survival (P =.87). Of the 12 sMTC tumors that underwent somatic testing, 11 (91%) had an identifiable alteration: 10 RET gene alterations and 1 ALK fusion. Conclusion sMTC is primarily a RET-driven disease that represents 14% of childhood-onset MTC in this cohort. Pediatric sMTC patients are older, present with clinical disease at a more advanced TNM classification, and have more persistent disease at last follow-up compared with hMTC, but these differences disappear when comparing those presenting clinically. Somatic molecular testing should be considered in sMTC patients who would benefit from systemic therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study

Author

Ahmed, Sairah, primary, Bashir, Qaiser, additional, Bassett, Roland L., additional, Ullah, Fauzia, additional, Aung, Fleur, additional, Valdez, Benigno C., additional, Alousi, Amin M., additional, Hosing, Chitra, additional, Kebriaei, Partow, additional, Khouri, Issa, additional, Marin, David, additional, Nieto, Yago, additional, Olson, Amanda, additional, Oran, Betul, additional, Qazilbash, Muzaffar H., additional, Rezvani, Katayoun, additional, Mehta, Rohtesh, additional, Shpall, Elizabeth J., additional, Ciurea, Stefan, additional, Andersson, Borje S., additional, Champlin, Richard E., additional, and Popat, Uday R., additional

Published
2024
Full Text
View/download PDF

22. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis

Author

Poon, Michelle L, Fox, Patricia S, Samuels, Barry I, O’Brien, Susan, Jabbour, Elias, Hsu, Yvonne, Gulbis, Alison, Korbling, Martin, Champlin, Richard, Abruzzo, Lynne V, Bassett, Roland L, and Khouri, Issa F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Stem Cell Research, Cancer, Stem Cell Research - Nonembryonic - Human, Clinical Research, Lymphoma, Rare Diseases, Hematology, Transplantation, Adult, Aged, Chromosome Deletion, Chromosomes, Human, Pair 17, Female, Follow-Up Studies, Graft vs Host Disease, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Referral and Consultation, Retrospective Studies, Stem Cell Transplantation, Survival Analysis, Survival Rate, Time Factors, Transplantation, Homologous, Treatment Outcome, 17p−, CLL, allogeneic transplant, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Allogeneic stem cell transplant (alloSCT) can overcome the adverse prognosis of chronic lymphocytic leukemia with 17p deletion (17p- CLL). However, its applicability remains unclear. Since 2007, our leukemia service has referred patients with 17p- CLL for alloSCT at presentation. In this study, the outcomes of these patients were reviewed retrospectively to determine whether they underwent alloSCT and why patients did not undergo alloSCT. Fifty-two patients with 17p- CLL who were referred to the transplant service from 2007 to 2010 were identified. Of these patients, 32 (62%) did not undergo alloSCT, mainly because of treatment- or disease-related complications (n = 15). The 2-year post-referral overall survival rates of the alloSCT and non-SCT groups were 64% and 25%, respectively (p = 0.001). These findings suggest that while alloSCT is an effective therapy in patients with 17p- CLL, pre-SCT complications may preclude a significant proportion of patients from undergoing the procedure.

Published
2015

23. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.

Author

Pasvolsky, Oren, Pasyar, Sarah, Bassett, Roland L., Khan, Hina N., Tanner, Mark R., Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Lee, Hans C., Patel, Krina K., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., and Qazilbash, Muzaffar H.

Subjects
HEMATOPOIETIC stem cell transplantation, MULTIPLE myeloma
Abstract

Background: The prognostic significance of minimal residual disease (MRD) status before autologous hematopoietic stem cell transplantation (autoHCT) in patients with multiple myeloma (MM) has not been clearly elucidated. Methods: Retrospective single‐center study of adult MM patients who achieved ≥very good partial response (VGPR) after induction therapy from 2015 to 2021 received upfront autoHCT and had available pretransplant MRD status by next‐generation flow cytometry. The cohort was divided into pretransplant MRD‐negative (MRDneg) and MRD‐positive (MRDpos) groups. Results: A total of 733 patients were included in our analysis; 425 were MRDneg and 308 MRDpos at autoHCT. In the MRDpos group, more patients had high‐risk cytogenetic abnormalities (48% vs. 38%, respectively; p =.025), whereas fewer patients achieved ≥CR before autoHCT (14% vs. 40%; p <.001). At day 100 after autoHCT, 37% of the MRDpos versus 71% of the MRDneg achieved ≥CR, and at best posttransplant response 65% versus 88% achieved ≥CR, respectively. After a median follow‐up of 27.6 months (range, 0.7–82.3), the median PFS was significantly shorter for patients in the MRDpos group compared to the MRDneg group: 48.2 months (95% confidence interval [CI], 0.3–80.5) versus 80.1 months (95% CI, 0.5–80.1), respectively (p <.001). There was no significant difference in overall survival between the two groups (p =.41). Pretransplant MRDpos status was predictive of shorter PFS in multivariate analysis (hazard ratio, 1.80; 95% CI, 1.31–2.46; p <.001). The impact of pretransplant MRD status was retained in most of the examined subgroups. Conclusions: In patients achieving ≥VGPR to induction, pretransplant MRDpos status was associated with a lower CR rate after autoHCT and a shorter PFS. This retrospective single‐center study evaluated the prognostic impact of pretransplant minimal residual disease (MRD) status by next‐generation flow cytometry in 733 multiple myeloma patients who achieved ≥ very good partial response after induction therapy and received upfront autologous hematopoietic stem cell transplantation (autoHCT). Pretransplant MRD positivity was associated with a lower complete remission rate after autoHCT and a shorter progression‐free survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation

Author

Pasvolsky, Oren, primary, Pasyar, Sarah, additional, Bassett, Roland L., additional, Khan, Hina N., additional, Tanner, Mark R., additional, Bashir, Qaiser, additional, Srour, Samer, additional, Saini, Neeraj, additional, Lin, Paul, additional, Ramdial, Jeremy, additional, Nieto, Yago, additional, Lee, Hans C., additional, Patel, Krina K., additional, Kebriaei, Partow, additional, Thomas, Sheeba K., additional, Weber, Donna M., additional, Orlowski, Robert Z., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2023
Full Text
View/download PDF

32. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Author

Abuhadra, Nour, primary, Sun, Ryan, additional, Bassett, Roland L., additional, Huo, Lei, additional, Chang, Jeffrey T., additional, Teshome, Mediget, additional, Clayborn, Alyson R., additional, White, Jason B., additional, Ravenberg, Elizabeth E., additional, Adrada, Beatriz E., additional, Candelaria, Rosalind P., additional, Yang, Wei, additional, Ding, Qingqing, additional, Symmans, W. Fraser, additional, Arun, Banu, additional, Damodaran, Senthil, additional, Koenig, Kimberly B., additional, Layman, Rachel M., additional, Lim, Bora, additional, Litton, Jennifer K., additional, Thompson, Alastair, additional, Ueno, Naoto T., additional, Piwnica-Worms, Helen, additional, Hortobagyi, Gabriel N., additional, Valero, Vicente, additional, Tripathy, Debu, additional, Rauch, Gaiane M., additional, Moulder, Stacy, additional, and Yam, Clinton, additional

Published
2023
Full Text
View/download PDF

33. Supplementary Figure from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma

Author

Saini, Neeraj Y., primary, Swoboda, David M., primary, Greenbaum, Uri, primary, Ma, Junsheng, primary, Patel, Romil D., primary, Devashish, Kartik, primary, Das, Kaberi, primary, Tanner, Mark R., primary, Strati, Paolo, primary, Nair, Ranjit, primary, Fayad, Luis, primary, Ahmed, Sairah, primary, Lee, Hun Ju, primary, Iyer, Swaminathan P., primary, Steiner, Raphael, primary, Jain, Nitin, primary, Nastoupil, Loretta, primary, Loghavi, Sanam, primary, Tang, Guilin, primary, Bassett, Roland L., primary, Jain, Preetesh, primary, Wang, Michael, primary, Westin, Jason R., primary, Green, Michael R., primary, Sallman, David A., primary, Padron, Eric, primary, Davila, Marco L., primary, Locke, Frederick L., primary, Champlin, Richard E., primary, Garcia-Manero, Guillermo, primary, Shpall, Elizabeth J., primary, Kebriaei, Partow, primary, Flowers, Christopher R., primary, Jain, Michael D., primary, Wang, Feng, primary, Futreal, Andrew P., primary, Gillis, Nancy, primary, Neelapu, Sattva S., primary, and Takahashi, Koichi, primary

Published
2023
Full Text
View/download PDF

34. Data from Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma

Author

Saini, Neeraj Y., primary, Swoboda, David M., primary, Greenbaum, Uri, primary, Ma, Junsheng, primary, Patel, Romil D., primary, Devashish, Kartik, primary, Das, Kaberi, primary, Tanner, Mark R., primary, Strati, Paolo, primary, Nair, Ranjit, primary, Fayad, Luis, primary, Ahmed, Sairah, primary, Lee, Hun Ju, primary, Iyer, Swaminathan P., primary, Steiner, Raphael, primary, Jain, Nitin, primary, Nastoupil, Loretta, primary, Loghavi, Sanam, primary, Tang, Guilin, primary, Bassett, Roland L., primary, Jain, Preetesh, primary, Wang, Michael, primary, Westin, Jason R., primary, Green, Michael R., primary, Sallman, David A., primary, Padron, Eric, primary, Davila, Marco L., primary, Locke, Frederick L., primary, Champlin, Richard E., primary, Garcia-Manero, Guillermo, primary, Shpall, Elizabeth J., primary, Kebriaei, Partow, primary, Flowers, Christopher R., primary, Jain, Michael D., primary, Wang, Feng, primary, Futreal, Andrew P., primary, Gillis, Nancy, primary, Neelapu, Sattva S., primary, and Takahashi, Koichi, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 1 and Supplementary Tables 1 through 3 from Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing

Author

Estrella, Jeannelyn S., primary, Tetzlaff, Michael T., primary, Bassett, Roland L., primary, Patel, Keyur P., primary, Williams, Michelle D., primary, Curry, Jonathan L., primary, Rashid, Asif, primary, Hamilton, Stanley R., primary, and Broaddus, Russell R., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Author

Chen, Pei-Ling, primary, Roh, Whijae, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Spencer, Christine N., primary, Prieto, Peter A., primary, Miller, John P., primary, Bassett, Roland L., primary, Gopalakrishnan, Vancheswaran, primary, Wani, Khalida, primary, De Macedo, Mariana Petaccia, primary, Austin-Breneman, Jacob L., primary, Jiang, Hong, primary, Chang, Qing, primary, Reddy, Sangeetha M., primary, Chen, Wei-Shen, primary, Tetzlaff, Michael T., primary, Broaddus, Russell J., primary, Davies, Michael A., primary, Gershenwald, Jeffrey E., primary, Haydu, Lauren, primary, Lazar, Alexander J., primary, Patel, Sapna P., primary, Hwu, Patrick, primary, Hwu, Wen-Jen, primary, Diab, Adi, primary, Glitza, Isabella C., primary, Woodman, Scott E., primary, Vence, Luis M., primary, Wistuba, Ignacio I., primary, Amaria, Rodabe N., primary, Kwong, Lawrence N., primary, Prieto, Victor, primary, Davis, R. Eric, primary, Ma, Wencai, primary, Overwijk, Willem W., primary, Sharpe, Arlene H., primary, Hu, Jianhua, primary, Futreal, P. Andrew, primary, Blando, Jorge, primary, Sharma, Padmanee, primary, Allison, James P., primary, Chin, Lynda, primary, and Wargo, Jennifer A., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Tables 1 - 11 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Author

Chen, Pei-Ling, primary, Roh, Whijae, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Spencer, Christine N., primary, Prieto, Peter A., primary, Miller, John P., primary, Bassett, Roland L., primary, Gopalakrishnan, Vancheswaran, primary, Wani, Khalida, primary, De Macedo, Mariana Petaccia, primary, Austin-Breneman, Jacob L., primary, Jiang, Hong, primary, Chang, Qing, primary, Reddy, Sangeetha M., primary, Chen, Wei-Shen, primary, Tetzlaff, Michael T., primary, Broaddus, Russell J., primary, Davies, Michael A., primary, Gershenwald, Jeffrey E., primary, Haydu, Lauren, primary, Lazar, Alexander J., primary, Patel, Sapna P., primary, Hwu, Patrick, primary, Hwu, Wen-Jen, primary, Diab, Adi, primary, Glitza, Isabella C., primary, Woodman, Scott E., primary, Vence, Luis M., primary, Wistuba, Ignacio I., primary, Amaria, Rodabe N., primary, Kwong, Lawrence N., primary, Prieto, Victor, primary, Davis, R. Eric, primary, Ma, Wencai, primary, Overwijk, Willem W., primary, Sharpe, Arlene H., primary, Hu, Jianhua, primary, Futreal, P. Andrew, primary, Blando, Jorge, primary, Sharma, Padmanee, primary, Allison, James P., primary, Chin, Lynda, primary, and Wargo, Jennifer A., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figures 1 - 13 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Author

Chen, Pei-Ling, primary, Roh, Whijae, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Spencer, Christine N., primary, Prieto, Peter A., primary, Miller, John P., primary, Bassett, Roland L., primary, Gopalakrishnan, Vancheswaran, primary, Wani, Khalida, primary, De Macedo, Mariana Petaccia, primary, Austin-Breneman, Jacob L., primary, Jiang, Hong, primary, Chang, Qing, primary, Reddy, Sangeetha M., primary, Chen, Wei-Shen, primary, Tetzlaff, Michael T., primary, Broaddus, Russell J., primary, Davies, Michael A., primary, Gershenwald, Jeffrey E., primary, Haydu, Lauren, primary, Lazar, Alexander J., primary, Patel, Sapna P., primary, Hwu, Patrick, primary, Hwu, Wen-Jen, primary, Diab, Adi, primary, Glitza, Isabella C., primary, Woodman, Scott E., primary, Vence, Luis M., primary, Wistuba, Ignacio I., primary, Amaria, Rodabe N., primary, Kwong, Lawrence N., primary, Prieto, Victor, primary, Davis, R. Eric, primary, Ma, Wencai, primary, Overwijk, Willem W., primary, Sharpe, Arlene H., primary, Hu, Jianhua, primary, Futreal, P. Andrew, primary, Blando, Jorge, primary, Sharma, Padmanee, primary, Allison, James P., primary, Chin, Lynda, primary, and Wargo, Jennifer A., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Methods, Figure Legends, Tables S1 - S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Author

Peng, Weiyi, primary, Chen, Jie Qing, primary, Liu, Chengwen, primary, Malu, Shruti, primary, Creasy, Caitlin, primary, Tetzlaff, Michael T., primary, Xu, Chunyu, primary, McKenzie, Jodi A., primary, Zhang, Chunlei, primary, Liang, Xiaoxuan, primary, Williams, Leila J., primary, Deng, Wanleng, primary, Chen, Guo, primary, Mbofung, Rina, primary, Lazar, Alexander J., primary, Torres-Cabala, Carlos A., primary, Cooper, Zachary A., primary, Chen, Pei-Ling, primary, Tieu, Trang N., primary, Spranger, Stefani, primary, Yu, Xiaoxing, primary, Bernatchez, Chantale, primary, Forget, Marie-Andree, primary, Haymaker, Cara, primary, Amaria, Rodabe, primary, McQuade, Jennifer L., primary, Glitza, Isabella C., primary, Cascone, Tina, primary, Li, Haiyan S., primary, Kwong, Lawrence N., primary, Heffernan, Timothy P., primary, Hu, Jianhua, primary, Bassett, Roland L., primary, Bosenberg, Marcus W., primary, Woodman, Scott E., primary, Overwijk, Willem W., primary, Lizée, Gregory, primary, Roszik, Jason, primary, Gajewski, Thomas F., primary, Wargo, Jennifer A., primary, Gershenwald, Jeffrey E., primary, Radvanyi, Laszlo, primary, Davies, Michael A., primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure S7 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Author

Peng, Weiyi, primary, Chen, Jie Qing, primary, Liu, Chengwen, primary, Malu, Shruti, primary, Creasy, Caitlin, primary, Tetzlaff, Michael T., primary, Xu, Chunyu, primary, McKenzie, Jodi A., primary, Zhang, Chunlei, primary, Liang, Xiaoxuan, primary, Williams, Leila J., primary, Deng, Wanleng, primary, Chen, Guo, primary, Mbofung, Rina, primary, Lazar, Alexander J., primary, Torres-Cabala, Carlos A., primary, Cooper, Zachary A., primary, Chen, Pei-Ling, primary, Tieu, Trang N., primary, Spranger, Stefani, primary, Yu, Xiaoxing, primary, Bernatchez, Chantale, primary, Forget, Marie-Andree, primary, Haymaker, Cara, primary, Amaria, Rodabe, primary, McQuade, Jennifer L., primary, Glitza, Isabella C., primary, Cascone, Tina, primary, Li, Haiyan S., primary, Kwong, Lawrence N., primary, Heffernan, Timothy P., primary, Hu, Jianhua, primary, Bassett, Roland L., primary, Bosenberg, Marcus W., primary, Woodman, Scott E., primary, Overwijk, Willem W., primary, Lizée, Gregory, primary, Roszik, Jason, primary, Gajewski, Thomas F., primary, Wargo, Jennifer A., primary, Gershenwald, Jeffrey E., primary, Radvanyi, Laszlo, primary, Davies, Michael A., primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

42. Data from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Author

Chen, Pei-Ling, primary, Roh, Whijae, primary, Reuben, Alexandre, primary, Cooper, Zachary A., primary, Spencer, Christine N., primary, Prieto, Peter A., primary, Miller, John P., primary, Bassett, Roland L., primary, Gopalakrishnan, Vancheswaran, primary, Wani, Khalida, primary, De Macedo, Mariana Petaccia, primary, Austin-Breneman, Jacob L., primary, Jiang, Hong, primary, Chang, Qing, primary, Reddy, Sangeetha M., primary, Chen, Wei-Shen, primary, Tetzlaff, Michael T., primary, Broaddus, Russell J., primary, Davies, Michael A., primary, Gershenwald, Jeffrey E., primary, Haydu, Lauren, primary, Lazar, Alexander J., primary, Patel, Sapna P., primary, Hwu, Patrick, primary, Hwu, Wen-Jen, primary, Diab, Adi, primary, Glitza, Isabella C., primary, Woodman, Scott E., primary, Vence, Luis M., primary, Wistuba, Ignacio I., primary, Amaria, Rodabe N., primary, Kwong, Lawrence N., primary, Prieto, Victor, primary, Davis, R. Eric, primary, Ma, Wencai, primary, Overwijk, Willem W., primary, Sharpe, Arlene H., primary, Hu, Jianhua, primary, Futreal, P. Andrew, primary, Blando, Jorge, primary, Sharma, Padmanee, primary, Allison, James P., primary, Chin, Lynda, primary, and Wargo, Jennifer A., primary

Published
2023
Full Text
View/download PDF

43. Data from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Author

Peng, Weiyi, primary, Chen, Jie Qing, primary, Liu, Chengwen, primary, Malu, Shruti, primary, Creasy, Caitlin, primary, Tetzlaff, Michael T., primary, Xu, Chunyu, primary, McKenzie, Jodi A., primary, Zhang, Chunlei, primary, Liang, Xiaoxuan, primary, Williams, Leila J., primary, Deng, Wanleng, primary, Chen, Guo, primary, Mbofung, Rina, primary, Lazar, Alexander J., primary, Torres-Cabala, Carlos A., primary, Cooper, Zachary A., primary, Chen, Pei-Ling, primary, Tieu, Trang N., primary, Spranger, Stefani, primary, Yu, Xiaoxing, primary, Bernatchez, Chantale, primary, Forget, Marie-Andree, primary, Haymaker, Cara, primary, Amaria, Rodabe, primary, McQuade, Jennifer L., primary, Glitza, Isabella C., primary, Cascone, Tina, primary, Li, Haiyan S., primary, Kwong, Lawrence N., primary, Heffernan, Timothy P., primary, Hu, Jianhua, primary, Bassett, Roland L., primary, Bosenberg, Marcus W., primary, Woodman, Scott E., primary, Overwijk, Willem W., primary, Lizée, Gregory, primary, Roszik, Jason, primary, Gajewski, Thomas F., primary, Wargo, Jennifer A., primary, Gershenwald, Jeffrey E., primary, Radvanyi, Laszlo, primary, Davies, Michael A., primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 1 from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Author

Davies, Michael A., primary, Fox, Patricia S., primary, Papadopoulos, Nicholas E., primary, Bedikian, Agop Y., primary, Hwu, Wen-Jen, primary, Lazar, Alexander J., primary, Prieto, Victor G., primary, Culotta, Kirk S., primary, Madden, Timothy L., primary, Xu, Quanyun, primary, Huang, Sha, primary, Deng, Wanleng, primary, Ng, Chaan S., primary, Gupta, Sanjay, primary, Liu, Wenbin, primary, Dancey, Janet E., primary, Wright, John J., primary, Bassett, Roland L., primary, Hwu, Patrick, primary, and Kim, Kevin B., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Data from Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

Author

Yam, Clinton, primary, Yen, Er-Yen, primary, Chang, Jeffrey T., primary, Bassett, Roland L., primary, Alatrash, Gheath, primary, Garber, Haven, primary, Huo, Lei, primary, Yang, Fei, primary, Philips, Anne V., primary, Ding, Qing-Qing, primary, Lim, Bora, primary, Ueno, Naoto T., primary, Kannan, Kasthuri, primary, Sun, Xiangjie, primary, Sun, Baohua, primary, Parra Cuentas, Edwin Roger, primary, Symmans, William Fraser, primary, White, Jason B., primary, Ravenberg, Elizabeth, primary, Seth, Sahil, primary, Guerriero, Jennifer L., primary, Rauch, Gaiane M., primary, Damodaran, Senthil, primary, Litton, Jennifer K., primary, Wargo, Jennifer A., primary, Hortobagyi, Gabriel N., primary, Futreal, Andrew, primary, Wistuba, Ignacio I., primary, Sun, Ryan, primary, Moulder, Stacy L., primary, and Mittendorf, Elizabeth A., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Materials and Methods from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Author

Davies, Michael A., primary, Fox, Patricia S., primary, Papadopoulos, Nicholas E., primary, Bedikian, Agop Y., primary, Hwu, Wen-Jen, primary, Lazar, Alexander J., primary, Prieto, Victor G., primary, Culotta, Kirk S., primary, Madden, Timothy L., primary, Xu, Quanyun, primary, Huang, Sha, primary, Deng, Wanleng, primary, Ng, Chaan S., primary, Gupta, Sanjay, primary, Liu, Wenbin, primary, Dancey, Janet E., primary, Wright, John J., primary, Bassett, Roland L., primary, Hwu, Patrick, primary, and Kim, Kevin B., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Table S1 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma

Author

Ekmekcioglu, Suhendan, primary, Davies, Michael A., primary, Tanese, Keiji, primary, Roszik, Jason, primary, Shin-Sim, Myung, primary, Bassett, Roland L., primary, Milton, Denái R., primary, Woodman, Scott E., primary, Prieto, Victor G., primary, Gershenwald, Jeffrey E., primary, Morton, Donald L., primary, Hoon, Dave S., primary, and Grimm, Elizabeth A., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 1 from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Author

Davies, Michael A., primary, Fox, Patricia S., primary, Papadopoulos, Nicholas E., primary, Bedikian, Agop Y., primary, Hwu, Wen-Jen, primary, Lazar, Alexander J., primary, Prieto, Victor G., primary, Culotta, Kirk S., primary, Madden, Timothy L., primary, Xu, Quanyun, primary, Huang, Sha, primary, Deng, Wanleng, primary, Ng, Chaan S., primary, Gupta, Sanjay, primary, Liu, Wenbin, primary, Dancey, Janet E., primary, Wright, John J., primary, Bassett, Roland L., primary, Hwu, Patrick, primary, and Kim, Kevin B., primary

Published
2023
Full Text
View/download PDF

50. Supplemantary Figure S1 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma

Author

Ekmekcioglu, Suhendan, primary, Davies, Michael A., primary, Tanese, Keiji, primary, Roszik, Jason, primary, Shin-Sim, Myung, primary, Bassett, Roland L., primary, Milton, Denái R., primary, Woodman, Scott E., primary, Prieto, Victor G., primary, Gershenwald, Jeffrey E., primary, Morton, Donald L., primary, Hoon, Dave S., primary, and Grimm, Elizabeth A., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results